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Abstract: The consumption of antioxidant-rich foods such as virgin olive oil (VOO) promotes
high-density lipoprotein (HDL) anti-atherogenic capacities. Intake of functional VOOs (enriched
with olive/thyme phenolic compounds (PCs)) also improves HDL functions, but the gene expression
changes behind these benefits are not fully understood. Our aim was to determine whether these
functional VOOs could enhance the expression of cholesterol efflux-related genes. In a randomized,
double-blind, crossover, controlled trial, 22 hypercholesterolemic subjects ingested for three weeks
25 mL/day of: (1) a functional VOO enriched with olive oil PCs (500 mg/kg); (2) a functional
VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT), and; (3) a natural
VOO (olive oil PCs: 80 mg/kg, control intervention). We assessed whether these interventions
improved the expression of cholesterol efflux-related genes in peripheral blood mononuclear cells by
quantitative reverse-transcription polymerase chain reactions. The FVOOT intervention upregulated
the expression of CYP27A1 (p = 0.041 and p = 0.053, versus baseline and the control intervention,
respectively), CAV1 (p = 0.070, versus the control intervention), and LXRβ, RXRα, and PPARβ/δ
(p = 0.005, p = 0.005, and p = 0.038, respectively, relative to the baseline). The consumption of a
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functional VOO enriched with olive oil and thyme PCs enhanced the expression of key cholesterol
efflux regulators, such as CYP27A1 and nuclear receptor-related genes.
Keywords: functional virgin olive oil; olive oil phenolic compounds; thyme phenolic compounds;
cholesterol efflux; HDL cholesterol; transcriptomics
1. Introduction
Virgin olive oil (VOO) consumption protects against the development of cardiovascular
diseases due to its richness in phenolic compounds (PCs) and other bioactive compounds such
as monounsaturated fatty acids [1–4]. Among its beneficial mechanisms, the intake of olive oil PCs has
been shown to promote major high-density lipoprotein (HDL) function, particularly cholesterol efflux
capacity (HDL’s ability to pick up cholesterol from macrophages), as well as other improvements in
HDL quality characteristics [5]. Going one step further, the consumption of enriched or functional
VOOs, supplemented with olive oil PCs or other complementary PCs such as those from thyme, has also
been shown to improve HDL functional traits and lipid profile [6–10], as well as other molecular
mechanisms potentially involved in the development of cardiovascular diseases [11,12]. On the one
hand, olive oil PCs are essentially monophenols such as hydroxytyrosol and tyrosol, whose effect on
cardiovascular protection [13] (mainly based on their capacity to neutralize pro-oxidant substances) may
be complemented with that from more complex PCs such as flavonoids (known to also be able to directly
modulate pro-inflammatory pathways such as those involving phosphoinositol-3-kinase/protein kinase
B, protein kinase C, and mitogen-activated protein kinases [14]). Beyond the antioxidant and
anti-inflammatory effect attributed to olive oil PCs [15,16], their capacity to modulate gene expression
is also essential to explain their health effects and those of the dietary patterns in which they are present,
such as the Mediterranean diet [17–19]. The benefits of this healthy dietary pattern could be partially
attributed to the protective capacities of VOO bioactive compounds on atherosclerosis and neoplastic
processes [20]. On the other hand, thyme bioactive compounds such as PCs and essential oils have
also been shown to be able to promote HDL cholesterol levels and to decrease low-density lipoprotein
cholesterol concentrations in diverse research models [21].
In relation to HDL functionality, the acute consumption of a VOO enriched with its own PCs
improved the expression of cholesterol efflux-related genes in pre-/hypertensive subjects in a previous
trial [22]. However, the effects of the sustained consumption of functional VOOs on the gene expression
related to cholesterol efflux and cholesterol metabolism regulation pathways have not been assessed to
date. Thus, the aim of the present study was to assess whether a sustained consumption of functional
VOOs (rich in complementary PCs from VOO or thyme) also promoted the expression of this gene
pathway, in order to contribute to explaining their potential benefits on HDL function and lipid profile.
2. Materials and Methods
2.1. Olive Oil Preparation
Two phenol-enriched VOOs (final PC concentration: 500 ppm) were prepared using as matrix a
low-phenolic-content VOO (80 ppm), which also served as the control. In particular, the characteristics
of the functional oils were: (1) a functional VOO enriched with an extra quantity of olive oil PCs
(500 ppm) (FVOO); and (2) a functional VOO enriched with olive oil (250 ppm) and thyme PCs
(250 ppm) (final PC concentration: 500 ppm) (FVOOT). Thyme PCs came from an aqueous thyme
extract, not from an essential oil. The procedure to obtain the phenolic extracts and the enriched oils
has been previously described [23].
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2.2. Study Design and Biological Samples
Thirty-three hypercholesterolemic volunteers (total cholesterol > 200 mg/dL) participated in a
randomized, double-blind, crossover, controlled trial in which we compared the effect of the three oils
previously described (FVOO, FVOOT, and the control VOO). The intervention consisted of three-week
periods in which the volunteers consumed 25 mL/day of raw VOO distributed along meals, preceded
by two-week wash-out periods with an olive oil very poor in PCs. All subjects gave their informed
consent for inclusion before they participated in the study. The study was conducted in accordance
with the Declaration of Helsinki, and the protocol was approved by the local Research and Ethics
Committees and registered with the International Standard Randomized Controlled Trial Number
ISRCTN77500181 [6].
In the course of the trial, we collected blood samples at fasting before and after each treatment,
in order to isolate peripheral blood mononuclear cells (which were conserved at −80 ◦C for
further analysis). We also collected EDTA plasma samples to determine glucose, total cholesterol,
and triglyceride concentrations using standard enzymatic automated methods in an ABX Pentra-400
autoanalyzer (ABX-Horiba Diagnostics, Montpellier, France), HDL cholesterol levels by an accelerator
selective detergent method (ABX-Horiba Diagnostics), and computed LDL cholesterol by the Friedewald
equation whenever triglycerides were <300 mg/dL. In this work, a sub-sample of 22 volunteers was
analyzed on the basis of sample availability and quality. Further details of the clinical trial and the
preparation of the functional oils have been thoroughly described in previous publications [6].
2.3. Gene Expression Analyses
First, we isolated total RNA from peripheral blood mononuclear cells from blood samples collected
from volunteers before and after the three VOO interventions by RNAeasy microkits (Qiagen, Hilden,
Germany), quantified total RNA, and checked RNA purity and integrity in a Nanoquant Bioanalyzer
(Tecan Ltd., Männedorf, Switzerland). We then converted RNA into complementary DNA using
High Capacity cDNA Reverse Transcription kits (Applied Biosystems-Life Technologies, Carlsbad,
CA, USA). Finally, we quantified gene expression by the quantitative retrotranscriptase real-time
polymerase chain reaction (qRT-PCR) technique, using TaqMan Low Density microfluidic cards
(Applied Biosystems-Life Technologies). We selected our candidate genes based on their relationship
with cholesterol efflux (cholesterol transporters and efflux transcriptional regulators). We analyzed the
data using the Sequence Detection System software 2.4 (Applied Biosystems-Life Technologies) and
calculated the changes in gene expression by the relative quantification method (applying the 2−∆∆Ct
formula) [22].
2.4. Sample Size
A sample size of 22 participants allowed ≥80% power to detect significant inter-group differences
of 0.26 units in the relative quantification of ATP-binding cassette, subfamily A1 (ABCA1) expression,
considering a two-sided type I error of 0.05, a dropout rate of 10%, and the standard deviation of the
differences of ABCA1 gene expression after an analogous intervention with a PC-rich VOO [22].
2.5. Statistical Analysis
We evaluated the normality of continuous variables by normal probability plots. We discarded
differences in baseline parameters between the eligible volunteers and the whole study population
with chi-squared tests, t-tests, and Mann-Whitney U tests (in categorical, normally, and non-normally
distributed continuous variables, respectively). We assessed the effects of each intervention relative to
baseline by paired t-tests, and the inter-treatment differences in mixed models adjusted for age and
sex, in which we also studied period-by-treatment interactions to discard possible carry-over effects.
To study whether the differences in gene expression variables after the oil interventions were related
among them, we assessed the associations among post-intervention changes by Spearman’s correlation
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analyses. We considered significant any p-value < 0.05 and performed all statistical analyses in R
Software (Vienna, Austria) v3.1.0 [24].
3. Results
3.1. Study Participants
The 22 eligible volunteers presented no differences in their baseline characteristics relative to the
whole trial population (Table 1).
Table 1. Study population.
Sub-Sample for
Transcriptomic
Analyses (N = 22)
Whole VOHF Study
Population (N = 33) p-Value
Age (years) 54.8 ± 8.94 55.5 ± 9.98 0.779
Male sex (n, %) 8 (36.4%) 14 (42.4%) 0.866
Glucose (mg/dL) 91.7 ± 13.5 90.8 ± 11.7 0.798
Total cholesterol (mg/dL) 227 ± 31.8 226 ± 35.2 0.968
HDL cholesterol (mg/dL) 31.1 ± 9.21 31.3 ± 10.4 0.952
LDL cholesterol (mg/dL) 171 ± 30.4 170 ± 32.2 0.906
Triglycerides (mg/dL) 116 [91.0; 139] 114 [88.0; 141] 0.790
Systolic blood pressure (mmHg) 128 ± 15.1 128 ± 14.6 0.863
Diastolic blood pressure (mmHg) 75.0 ± 10.8 73.2 ± 10.0 0.536
Body mass index (kg/m2) 26.6 ± 4.00 26.6 ± 4.45 0.999
Smokers (n, %) 1 (4.55%) 2 (6.06%) 1.000
Variables are expressed as percentages (categorical variables), means ± standard deviation (normally distributed
variables) or median [1st; 3rd quartile] (non-normally distributed variables).
3.2. Gene Expression Analyses
FVOOT intake upregulated significantly the expression of cytochrome P450, subunit 27A1
(CYP27A1; p = 0.041), liver X receptor beta (LXRβ; p = 0.005), peroxisome-proliferator activated receptor
beta/delta (PPARβ/δ; p = 0.038), and retinoid X receptor alpha (RXRα; p = 0.005), and the expression
of ABCA1 in a marginally significant way (p = 0.099), relative to baseline in all cases. Upregulation
of caveolin-1 (CAV-1), CYP27A1, and LXRβ was marginally significant relative to the VOO control
intervention (p = 0.070, p = 0.053, and p = 0.070, respectively). Finally, VOO intake downregulated
RXRβ expression relative to baseline (p = 0.025) (Table 2).
CAV1, CYP27A1, LXRβ, PPARβ/δ, and RXRα upregulation after the FVOOT intervention were
intimately inter-correlated and associated with increments in ABCA1 expression (r > 0.55, p < 0.0042
-adjusted p-value for 12 comparisons, according to the Bonferroni method-) (Figure 1).
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Table 2. Gene expression changes after olive oil interventions.
FVOOT Intervention FVOO Intervention VOO Intervention
Post-Intervention
Value
Post- vs. Pre-
Intervention
Difference
FVOOT vs.
VOO p-Value
Post-Intervention
Value
Post- vs. Pre-
Intervention
Difference
FVOO vs.
VOO p-Value
Post-Intervention
Value
Post- vs. Pre-
Intervention
Difference
ABCA1 0.82 ± 0.60 0.23 ± 0.14 0.402 0.92 ± 0.59 0.15 ± 0.14 0.666 0.87 ± 0.65 0.064 ± 0.14
ABCG1 0.63 ± 0.79 −0.032 ± 0.10 0.588 0.75 ± 0.79 −0.048 ± 0.10 0.663 0.74 ± 0.77 −0.11 ± 0.11
CAV1 1.43 ± 0.93 0.16 ± 0.15 0.070 1.37 ± 1.02 −0.19 ± 0.15 0.814 1.63 ± 1.02 −0.24 ± 0.15
CYP27A1 −0.89 ± 0.81 0.48 ± 0.23 * 0.053 −0.79 ± 0.90 0.24 ± 0.23 0.216 −0.94 ± 0.81 −0.17 ± 0.24
NR1H2 (LXRβ) 0.57 ± 0.6 0.57 ± 0.20 ** 0.070 0.57 ± 0.61 0.052 ± 0.20 0.977 0.62 ± 0.59 0.043 ± 0.21
NR1H3 (LXRα) 0.79 ± 0.51 −0.055 ± 0.12 0.448 0.74 ± 0.59 −0.22 ± 0.12 0.850 0.91 ± 0.58 −0.18 ± 0.12
PPARA 0.14 ± 0.44 0.14 ± 0.12 0.249 0.20 ± 0.52 0.018 ± 0.12 0.661 0.28 ± 0.48 −0.06 ± 0.13
PPARD −0.37 ± 0.56 0.23 ± 0.11 * 0.206 −0.30 ± 0.60 0.12 ± 0.11 0.573 −0.32 ± 0.52 0.029 ± 0.11
PPARG −0.11 ± 1.11 0.19 ± 0.20 0.353 −0.12 ± 1.12 0.20 ± 0.20 0.330 −0.12 ± 1.18 −0.079 ± 0.21
RXRA 0.22 ± 0.54 0.62 ± 0.21 ** 0.132 0.24 ± 0.58 0.071 ± 0.22 0.790 0.32 ± 0.60 0.15 ± 0.22
RXRB 0.76 ± 0.63 −0.050 ± 0.16 0.166 0.80 ± 0.67 −0.16 ± 0.16 0.368 0.89 ± 0.69 −0.37 ± 0.16 *
SCARB1 0.22 ± 0.69 0.12 ± 0.10 0.367 0.19 ± 0.76 0.018 ± 0.10 0.845 0.31 ± 0.72 −0.010 ± 0.10
ABCA1: ATP-binding cassette A1; ABCG1: ATP-binding cassette G1; CAV1: caveolin-1; CYP27A1; cytochrome P450, family 27, subunit A1; FVOO: functional virgin olive oil enriched with
olive oil phenolic compounds (500 mg/kg); FVOOT: functional virgin olive oil enriched with olive oil (250 mg/kg) + thyme phenolic compounds (250 mg/kg); NR1H2-LXRβ: liver X
receptor beta; NR1H3-LXRα: liver X receptor alpha; PPARA: peroxisome proliferator-activated receptor alpha; PPARD: peroxisome proliferator-activated receptor beta/delta; PPARG:
peroxisome proliferator-activated receptor gamma; RXRA: retinoic X receptor alpha; RXRB: retinoic X receptor beta; SCARB1: scavenger receptor B-1; VOO: natural virgin olive oil
(80 mg/kg). Variables are expressed as means ± standard errors of the mean. Intra-treatment comparisons: *: p < 0.05; **: p < 0.01.
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Figure 1. Significant Spearman’s correlation values of differences after the FVOOT intervention
(adjusted for multiple comparisons according to the Bonferroni correction method, p < 0.0042).
4. Discussion
In the present work, we report that the consumption of a functional VOO, enriched with olive oil
and thyme PCs, enhanced the expression of key cholesterol efflux genes.
The ability of HDL to promote cholesterol efflux from macrophages is the most studied HDL
function and reflects HDL anti-atherogenic role better than HDL cholesterol levels [25]. Lipid-poor and
small HDLs mediate cholesterol efflux by binding to ABCA1 (in a cellular system intimately related
to caveolae/CAV1 gene expression in immune cells such as macrophages) [26] and large HDLs exert
this process via ATP-binding cassette G1 and scavenger receptor B1. Expression of these cholesterol
transporters is mainly regulated by LXRs and PPARs, key transcription factors in the overall regulation
of lipid metabolism [25,26]. In our study, consumption of the FVOOT functional oil promoted LXR
gene expression and activation through two hypothetical pathways (Scheme 1): (1) the upregulation of
CYP27A1 (a monooxygenase member of the cytochrome P450 superfamily), enzyme responsible for
the transformation of cholesterol into oxidized sterols, essential activator ligands of LXR; and (2) the
upregulation of RXRα, whose correspondent protein is necessary to build the LXR-RXR heterodimer
(the active complex responsible for LXR nuclear functions) [27]. A quantitative proteomic approach
performed in our study had already reported an increase in the levels of several proteins related to the
LXR/RXR axis after the functional and the control VOO interventions [28]. Activation of LXR function
has been consistently linked to increments in the expression of cholesterol transporters involved in the
efflux phenomenon (such as ABCA1 and ABCG1) [25] and of CAV1 [26]. In addition, FVOOT intake
upregulated PPARβ/δ, another transcription factor known to induce the expression of ABCA1 [29] and
CAV1 [30]. Increases in the expression of RXR may be additionally related to a greater activation of
this PPAR (its active form is also a heterodimer with RXR), which, in turn, is also known to promote
LXR function [29].
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Sche e 1. odulation of cholesterol efflux-related transcriptional regulators due to a functional virgin
olive oil enriched in olive oil and thyme phenolic compounds.
Olive oil and thyme PCs are not the only known to be able to modulate cholesterol
metabolism-related gene expression pathways. Other bioactive dietary compounds such as curcumin
and 6-dihydroparadol from ginger, and coenzyme Q10 have been shown to promote cholesterol
efflux-related gene expression in previous in vitro or in vivo studies [31,32]. Furthermore, nutritional
supplements of green tea catechins have also been associated with a promotion of the RXR expression
in animal models [33]. Finally, coenzyme Q10 treatment promoted ABCG1-mediated macrophage
cholesterol efflux in a randomized trial in healthy volunteers [34]. Upregulation of some of these genes
(PPAR-related, ABCA1, and SRB1) has also been reported after an acute consumption of a PC-rich VOO
in pre-/hypertensive subjects [22]. However, in the present study, the FVOOT intervention promoted
the expression of cholesterol-efflux regulatory genes only versus their baseline, although marginally
significant increases in their expression were also observed relative to the control intervention.
Differences among studies can be explained by the extremely high content in PCs administered in the
previous work [22], the study design (acute use versus mid-term sustained consumption), and the
pathophysiology of the participants (hypertensive versus hypercholesterolemic).
The greatest strength of this study is its randomized, crossover, double-blind, controlled design,
which confers strong inter-individual variability control. However, it also presents limitations: the
observed effects were expectedly modest, since our trial was based on oil doses that could be achievable
via a regular diet, and the control intervention was a VOO (with a considerable amount of olive oil
PCs, 80 ppm), which makes it more difficult to observe inter-group differences.
5. Conclusions
A f nctional VOO, enriched with olive oil and thyme PCs (250 mg/kg of each), promoted the
expression of several genes regulating HDL cholesterol efflux capacity (CAV1, CYP27A1, LXRβ, PPARβ/δ,
RXRα). Such an improvement may contribute to explaining the beneficial effect of this functional food
product on HDL functional capacities in hypercholesterolemic patients. These results contribute to
explaining the beneficial effects of these functional oils towards a more cardioprotective lipid profile.
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